References
- Luigetti M, Romano A, Di Paolantonio A, et al. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109–123.
- Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31
- Ohmori H, Ando Y, Makita Y, et al. Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. J Med Genet. 2004 Apr;41(4):e51
- Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016 Feb;29(Suppl 1):S14–26
- Coelho T, Ines M, Conceicao I, et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018 Nov 20;91(21):e1999–e2009.
- Adams D, Ando Y, Beirao JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020 Jan 6.
- Gonzalez-Duarte A, Conceicao I, Amass L, et al. Impact of Non-cardiac clinicopathologic characteristics on survival in transthyretin amyloid polyneuropathy. Neurol Ther. 2020 Jun;9(1):135–149
- European Medicines Agency: Vyndaqel. Vyndaqel [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel
- European Medicines Agency: Tegsedi. Tegsedi [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi
- European Medicines Agency: Onpattro. Onpattro [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/onpattro
- Coelho T, Maia LF, Martins Da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012 Aug 21;79(8):785–792.
- Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11–21.
- Benson M, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22–31.
- Buades Reines J, Vera TR, Martin MU, et al. Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: son Llatzer Hospital descriptive study. Orphanet J Rare Dis. 2014 Feb 26;9:29
- Stewart M, Shaffer S, Murphy B, et al. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018 Dec;7(2):349–364
- European Central Bank. HICP - Indices, breakdown by purpose of consumption. Sept 2020 [cited 2020 Oct 09] . Available at: https://www.ecb.europa.eu/stats/ecb_statistics/escb/html/table.en.html?id=JDF_ICP_COICOP_INX
- Summary of Product Characteristics [Internet]. 2016 [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf
- Summary of Product Characteristics [Internet]. 2018 [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/documents/product-information/onpattro-epar-product-information_en.pdf.
- Summary of Product Characteristics [Internet]. 2018 [cited 2020 Mar 20]. Available at: https://www.ema.europa.eu/en/documents/product-information/tegsedi-epar-product-information_en.pdf
- Real-Decreto-Ley-8/2010,m.2010. Available from: http://www.boes.es
- BotPlus. Consejo General de Colegios Oficiales de Farmacéuticos 2020 [cited 2020 Jun 06]. Available at: https://botplusweb.portalfarma.com/
- [Base de datos de costes sanitarios eSalud]. Barcelona: oblikue consulting, [Internet]. 2020 [cited 2020 Feb 13]. Available at:
- Scientificfilters.com. 2020 [cited 2020 Jun 08]. Available at: scientificfilters.com/membrane-filters/pes
- Ines M, Coelho T, Conceicao I, et al. Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy. Amyloid. 2020 Jun;27(2):89–96
- Munar-Ques M, Saraiva MJ, Viader-Farre C, et al. Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid. 2005 Mar;12(1):54–61
- Ayuntamiento DM [cited 2020 Feb 17]. Available at: https://www.madrid.es/UnidadesDescentralizadas/UDCMovilidadTransportes/SER/Descriptivos/ficheros/Tarifas%20SER%20desde%2001_06_2017.pdf
- Instituto national de estadistica. [cited 2020 Feb 17]. Available at: https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736060920&menu=ultiDatos&idp=1254735976596
- Oliva-Moreno J, Pena-Longobardo LM, Garcia-Mochon L, et al. The economic value of time of informal care and its determinants (The CUIDARSE Study). PLoS One. 2019;14(5):e0217016
- Kelly C, Hulme C, Farragher T, et al. Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review. BMJ Open. 2016 Nov 24;6(11):e013059.
- National Institute for Health Excellence. Highly specialised technology evaluation: patisiran for treating hereditary transthyretin amyloidosis. 2018.
- Samjoo IA, Salvo EM, Tran D, et al. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy. Curr Med Res Opin. 2020 May;36(5):799–808